drugset / Trial / NCT05909943
Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
NaSingle-groupOpen-labelBasic science
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.
Timeline
- Start
- 2024-06-01
- Primary completion
- 2026-02-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |